Johns Hopkins Medicine: Study Shows FDA-Approved TB Regimen May Not Work Against The Deadliest Form Of TB Due To Multidrug-Resistant Strains
January 28, 2023
January 28, 2023
BALTIMORE, Maryland, Jan. 28 (TNSjou) -- Johns Hopkins Medicine issued the following news release:
Findings from a Johns Hopkins Children's Center study in animal models show that a U.S. Food and Drug Administration (FDA)-approved antibiotic regimen for multidrug-resistant (MDR) tuberculosis (TB) may not work for TB meningitis. Studies in a small number of people also provide evidence that a new combination of drugs is needed to develop effective treatments for TB meningitis du . . .
Findings from a Johns Hopkins Children's Center study in animal models show that a U.S. Food and Drug Administration (FDA)-approved antibiotic regimen for multidrug-resistant (MDR) tuberculosis (TB) may not work for TB meningitis. Studies in a small number of people also provide evidence that a new combination of drugs is needed to develop effective treatments for TB meningitis du . . .